Effectors of fatty acid oxidation reduction: Promising new anti-ischaemic agents

Current Pharmaceutical Design

Volumn 11, Issue 4, 2005, Pages 489-509

  Grynberg, Alain ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; AMIODARONE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CARNITINE DERIVATIVE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; DICHLOROACETIC ACID; DILTIAZEM; DOBUTAMINE; DOCOSAHEXAENOIC ACID; EMERIAMINE; ETHYLENE OXIDE; ETOMOXIR; FATTY ACID; GAMMA BUTYROBETAINE; METOPROLOL; MILDRONATE; NIFEDIPINE; OXFENICINE; OXYGENASE INHIBITOR; PALMOXIRIC ACID; PERHEXILINE; PROPIONYLCARNITINE; PROPRANOLOL; RANOLAZINE; TRIMETAZIDINE; UNINDEXED DRUG;

ANGINA PECTORIS; CARNITINE DEFICIENCY; CLINICAL TRIAL; DIETARY INTAKE; DRUG DESIGN; ENERGY METABOLISM; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE OXIDATION; HEART FAILURE; HEART HEMODYNAMICS; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTRIGLYCERIDEMIA; LIPIDOSIS; LIVER DYSFUNCTION; METABOLIC BALANCE; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION REACTION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW;

ACYL COENZYME A; ANIMALS; CARDIOVASCULAR AGENTS; CARNITINE O-PALMITOYLTRANSFERASE; CLINICAL TRIALS; FATTY ACIDS; FATTY ACIDS, OMEGA-3; GLUCOSE; HUMANS; MITOCHONDRIA, HEART; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION;

EID: 13444301533     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382061     Document Type: Review

References (207)

1. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C. et al. Effects of an intravenous infusion of potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 962; 9: 166-81.
2. Sodi-Pallares D, Bisteni A, Medrano GA, Testelli MR, DeMicheli A. The polarizing treatment of acute myocardial infarction. Dis Chest 1963; 43: 424-32.
3. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo-controlled trials. Circulation 1997; 96: 1152-56.
4. Lazar HL. Enhanced preservation of acutely ischaemic myocardium and improved clinical outcomes using glucose-insulin-potassium (GIK) solutions. Am J Cardiol 1997; 80: 90A-93A.
5. Doenst T, Bothe W, Beyersdorf F. Therapy with insulin in cardiac surgery: controversies and possible solutions. Ann Thorac Surg 2003; 75: S721-8.
6. Opie L. The heart. Physiology and metabolism. Raven Press, New York 1991.
7. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance in heart muscle. Ann Rev Physiol 1974; 36: 413-59.
8. Drake AJ, Haines JR, Noble MIM. Preferencial uptake or lactate by the normal myocardium in dogs. Cardiovasc Res 1980; 14: 65-72.
9. Tani M, Neely JR. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischaemic rat hearts. Possible involvement of H+-Na+ and Na+-Ca2+ exchange. Circ Res 1989; 65: 1045-56.
10. Saddik M, Gamble J, Witters LA, Lopaschuk GD. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 1993; 268: 25836-45.
11. Pauly DF, Kirk KA, McMillin JB. Carnitine palmitoyl transferase in cardiac ischaemia. A potential site for altered fatty acid metabolism. Circ Res 1991; 68: 1085-1094.
12. Kudo N, Barr A, Barr R, Lopaschuk GD. 5′AMP activated protein kinase inhibition of acetyl CoA carboxylase can explain the high rates of fatty acid oxidation in the reperfused ischaemic heart. J Biol Chem 1995; 270: 17511-20.
13. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev 2002; 7: 149-59.
14. Wojtczak L, Schöfeld P. Effect of fatty acid on energy coupling process in mitochondria. Biochem Biophys Acta 1993; 1183: 41-57.
15. Hütter JF, Soboll S. Role of fatty acid metabolites in the developpement or myocardial ischaemic damage. Int. J. Biochem 1992; 24: 399-403.
16. Rausch B, Bode C, Piper HM, Hütter JF, Zimmermann R, Braunwell E, et al. Palmilate uptake by calcium tolerant, adult rat myocardial single cells: evidence for an albumin mediated transport across sarcolemma. J Mol Cell Cardiol 1987; 19: 159-166.
17. Schulz H. Beta-oxydation of fatty acids. Biochim Biophys Acta 1991; 1081: 109-120.
18. Stremmel W, Pohl L, Ring A, Herrmann T. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 2001; 36: 981-9.
19. van der Vusse GJ, van Bilsen, M, Glatz JF, Hasselbaink DM, Luiken JJ. Critical steps in cellular fatty acid uptake and utilization. Mol Cell Biochem 2002; 239: 9-15.
20. Glatz JF, van Nieuwenhoven FA, Luiken JJ, Schaap FG, van der Vusse GJ. Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism Prostaglandins Leukot Essent Fatty Acids 1997; 57: 373-8.
21. Bersin RM, Stacpoole PW. Dichloroacetate as metabolic therapy for myocardial ischaemia and failure. Am Heart J 1997: 134: 841-55.
22. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischaemic rat hearts. Am J Physiol 1990; 259: H1079-85.
23. Wambolt RB, Lopaschuk GD, Brownsey RW, Allard MF. Dichloroacetate improves postischaemic function of hypertrophied rat hearts. J Am Coll Cardiol 2000; 36: 1378-85.
24. Schoder H, Knight RJ, Kofoed KF, Schelbert HR, Buxton DB. Regulation of pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic myocardium. Biochim Biophys Acta 1998; 1406: 62-72.
25. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K. et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994; 23: 1617-24.
26. Zammit VA. Carnitine acyltransferases: functional significance of subcellular distribution and membrane topology. Prog Lipid Res 1999; 38: 199-224.
27. Ramsay RR, Tubbs PK. The mechanism of fatty acid uptake by heart mitochondria: an acylcarnitine-carnitine exchange. FEBS Lett 1975; 54: 21-5.
28. McGarry JD. Travels with carnitine palmitoyltransferase I: from liver to germ cell with stops in between. Biochem Soc Trans 2000; 29: 241-5.
29. Eaton S, Fukumoto K, Paladio Duran N, Pierro A, Spitz L, Quant PA, et al. Carnitine palmitoyl transferase I and the control of myocardial beta-oxidation flux. Biochem Soc Trans 2001; 29: 245-50.
30. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 1992; 15: 773-84.
31. Hubinger A, Weikert G, Wolf HP, Gries FA. The effect of etomoxir on insulin sensitivity in type 2 diabetic patients. Horm Metab Res 1992; 24: 115-8.
32. Rosen P, Schmitz FJ, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the palmitoylcarnitine inhibitor etomoxir. In "Cardiovascular disease in diabetes" Eds Nagano M, Moshizuki S, Dhalla NS, Kluwer, Boston 1992; 361-72.
33. Selby PL, Sherratt HSA. Substituted 2-oxirane carboxylic acids: a new group or hypoglyceamic drugs. Trends Pharmacol Sci 1989; 35: 4267-4272.
34. Lopaschuk GD, Wall SR, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischaemic injury independent of changes in long chain acylcarnitine. Circ Res 1988; 63: 1036-43.
35. Hegardt FG, Serra D, Asins G. Influence of etomoxir on the expression of several genes in liver, testis and heart. Gen Pharmacol 1995; 26: 897-904.
36. Rupp H, Elimban V, Dhalla NS. Modification of subcellular organelles in pressure overloaded heart by etomoxir, a palmitoyl carnitine transferase I inhibitor. FASEB J 1992; 6: 2349-53.
37. Rupp H, Jacob R. Metabolically modulated growth and phenotype of the rat hear. Eur Heart J 1992; 13 Suppl D: 56-61.
38. Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002; 27: 621-36.
39. Rupp H, Schulze W, Vetter R. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir. Am J Physiol 1995; 269: R630-40.
40. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000; 278: F667-75.
41. Panos TC, Finerty JC. Effect of fat free diet on growing female rats, with special reference to endocrine system. J Nutr 1953; 49: 397-418.
42. Cabrero A, Merlos M, Laguna JC, Carrera MV. Down-regulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res 2003; 4: 388-98.
43. Hinderling VB, Schrauwen P, Langhans W, Westerterp-Plantenga MS. The effect of etomoxir on 24-h substrate oxidation and satiety in humans. Am J Clin Nutr 2002; 76: 141-7.
44. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000 ; 99: 27-35.
45. Bachmann E, Weber E. Biochemical mechanisms of oxfenicine cardiotoxicity. Pharmacology 1988; 36: 238-48.
46. Vik-Mo H, Mjos OD, Neely JR, Maroko PR, Ribeiro LG. Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischaemic myocardium. Am Heart J 1986; 111: 1048-54.
47. Molaparast-Saless F, Liedtke AJ, Nellis SH. Effects of the fatty acid blocking agents, oxfenicine and 4-bromocrotonic acid, on performance in aerobic and ischaemic myocardium. J Mol Cell Cardiol 1987; 19: 509-20.
48. Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS, Stanley WC. Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischaemia. Cardiovasc Res 2003; 59: 143-51.
49. Greaves P, Martin J, Michel MC, Mompon P. Cardiac hypertrophy in the dog and rat induced by oxfenicine, an agent which modifies muscle metabolism. Arch Toxicol Suppl 1984; 7: 488-93.
50. Hamdan M, Urien S, Le Louet H, Tillement JP, Morin D. Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176. Pharmacol Res 2001; 44: 99-104.
51. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52: 273-80.
52. Panchal AR, Stanley WC, Kerner J, Sabbah HN. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 1998; 4: 121-6.
53. Lee SM, Bahl JJ, Bressler R. Prevention of the metabolic effects of 2-tetradecylglycidate by octanoic acid in the genetically diabetic mouse (db/db). Biochem Med 1985; 33: 104-9.
54. Hulsmann WC, Schneijdenberg CT, Verkleij AJ. Accumulation and excretion of long-chain acylcarnitine by rat hearts; studies with aminocarnitine. Biochim Biophys Acta 1991; 1097: 263-9.
55. Chiodi P, Maccari F, Ramacci MT. Tissue lipid accumulation by L-aminocarnitine, an inhibitor of carnitine-palmitoyltransferase-2. Studies in intact rats and isolated mitochondria. Biochim Biophys Acta 1992: 1127: 81-6.
56. Winter SC, Buist NR. Cardiomyopathy in childhood, mitochondrial dysfunction and the role of L-carnitine. Am Heart J 2000; 139: S63-9.
57. Retter AS. Carnitine and its role in cardiovascular disease. Heart Dis 1999; 1: 108-13.
58. Böhles H, Noppeney T, Akcetin Z, Rein J, Von der Emde J. The effect or preoperative L-carnitine supplementation on myocardial metabolism during aorta-coronary bypass surgery. Z Kardiol 1987: 76 Suppl 5: 14-8.
59. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 2000; 95: 75-83.
60. Lopaschuk GD. Regulation of carbohydrate metabolism in ischaemia and reperfusion. Am Heart J 2000; 139: S115-9.
61. Bartels GL, Remme WJ, Holwerda KJ, Kruijssen DA. Anti-ischaemic efficacy of L-propionylcarnitine - a promising novel metabolic approach to ischaemia? Eur Heart J 1996; 17: 414-20.
62. Bartel GL, Remme WJ, den Hartog FR, Wielenga RP, Kruijssen DA. Additional antiischaemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Cardiovasc Drugs Ther 1995; 9: 749-53.
63. Simkhovich BZ, Shutenko ZV, Meirena DV, Khagi KB, Mezapuke RJ, Molodchina TN, et al. 3-(2, 2, 2-Trimethyl hydrazinium) propionate (THP) - a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 1988; 37: 195-202.
64. Shutenko ZhV, Priedena IA, Kalvin'sh IIa, Lukevits EIa. The effect of a structural analog of gamma-butyrobetaine, mildronate, [3-2, 2, 2-trimethylhydrazine)propionate] on dynamic carnitine-dependent metaboli Vopr Med Khim 1991; 37: 24-6.
65. Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Stieger B, et al. Development and characterization of an animal model of carnitine deficiency. Eur J Biochem 2001; 268: 1876-87.
66. Kirimoto T, Nobori K, Asaka N, Muranaka Y, Tajima K, Miyake H. Beneficial effect of MET-88, a gamma-butyrobetaine bydroxylase inhibitor, on energy metabolism in ischaemic dog hearts. Arch Int Pharmacodoyn Ther 1996; 331: 163-78.
67. Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N. Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur J Pharmacol 2000; 395: 217-24.
68. Stebleva TF, Voitovich AV, Mamaeva EG, Lapshangskaia EE, Semigolovskii Nlu, Lebedinskii KM. Mechanisms of the optimization or oxygen metabolism under the effects of mafusol and mildronate during emergency implantation of hip prosthesis. Vestn Khir Im I I Grek 2000; 159: 57-60.
69. Nedoshivin AO, Petrova NN, Kutuzova AE, Perepech NB. Effect of mildronate on life quality of patients with chronic heart failure. Ter Arkh 1999; 71: 10-2.
70. Tepliakov AT, Sankevich TV, Stepacheva TA, Mamchur SE. The Use Fatty Acid of beta-Oxidation Inhibitor Mildronate as Monotherapy or in Combination With Atenolol in Patients With Left Ventricular Dysfunction After Myocardial Infarction. Kardiologiia 2003; 43: 15-8.
71. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 2002; 12: 275-9.
72. Tsoko M, Beauseigneur F, Gresti J, Niot I, Demarquoy J, Boichot J, et al. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of L-carnitine by D-carnitine and a gamma-butyrobetaine hydroxylase inhibitor. Biochem Pharmacol 1995; 49: 1403-10.
73. Bennett MJ, Rinaldo P, Strauss AW. Inborn errors of mitochondrial fatty acid oxidation. Crit Rev Clin Lab Sci 2000; 37: 1-44.
74. Przyrembel H, Sewell AC. Defects long chain fatty acid oxidation as a cause of cardiomyopathy. in "Metabolic Cardiomyopathy. Böhles H, Hofstetter R, Sewell AC. Eds". Wissenschaftliche Verlagsgesellschaft, Stuttgart. 1995: pp 77-85.
75. Stanley WC. Partial inhibition of cardiac fatty acid oxidation for the treatment of chronic stable angina. Expert Opin Invest Drugs 2002; 11: 1-15.
76. Sellier P, Audouin P, Payen B, Corona P, Duong TC, Ourbak P. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol 1987; 33: 205-7.
77. Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study. Arch Mal Cocur Vaiss. 1986; 79: 1331-6.
78. Dalla-Volta S, Marglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990; 4: 853-9.
79. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279-88.
80. Dargie HJ, Ford I, Fox KM. Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17: 104-12.
81. Savonitto S, Ardissiono D, Egstrup K, Rasmussen K, Bae EA, Omland T, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996; 27: 311-6.
82. Madjlessi-Simon T, Fillette F, Mary-Krause M, Lechat P, Jaillon P. Effects of amlodipine on transient myocardial ischaemia in patients with a severe coronary condition treated with a beta-blocker. Amlor-Holter Study Investigators. Eur Heart J 1995; 16: 1780-8.
83. de Vries RJ, Dunselman PH, van Veldhuisen DJ, van den Heuvel AF, Wielenga RP, Lie KI. Comparison between felodipine and isosorbide mononitrate as adjunct to beta blockade in patients >65 years of age with angina pectoris. Am J Cardiol 1994; 74: 1201-6.
84. Monpère C, Brochier M, Demange J, Ducloux C, Warin JF. Combination of trimetazidine with nifedipine in effort angina. Cardiovasc Drug Ther 1990; 4: 824-825.
85. Levy S, and the group of the south of France investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am. J. Cardiol 1995; 76: 12B-16B.
86. Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353-7.
87. Michaelides AP, Vyssoulis Gp, Bonoris PE, Psaros TK, Papadopoulos PD, Toutouzas PK. Beneficial Effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Ther Res 1989; 46: 565-76.
88. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22: 2267-74.
89. Szwed H, Hradec J, Preda I. Anti-ischaemicc efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies. Coron Artery Dis 2001; 12 (Suppl 1) S25-8
90. Michaelides AP, Spiropoulos K, Dimopoulos K, Athanasiades D, Toutouzas P. Antianginal efficacy or the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 8-14.
91. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 1992; 13: 1109-15.
92. Szwed H, Sadowski Z, Pachocki R, Domzal-Bochenska M, Szymczak K, Szydlowski Z, et al. The antiischaemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther 1999; 13: 217-22.
93. Nedoshivin AO, Kutuzova AE, Nesterova IV, Mikhailova IE, Rubashkina EI, Novikova NA, et al. Trimetazidine in correction of chronic heart failure in patients with ischaemic heart disease. Kardiologiia 2002; 42: 12-5.
94. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine, Fundam Clin Pharmacol 2003; 17: 133-45.
95. McClellan KJ, Plosker CL. Trimetazidine. A review of its use in stable anginapectoris and other coronary conditions. Drugs 1999; 58: 143-57.
96. Coyas A. The efficacy of trimetazidine in cochleovestibular disorders of ischaemic origin. A crossover control versus placebo trial. Ann Otolaryngol Chir Cervicofac 1990; 107 Suppl 1: 82-7.
97. Wayoff M. Evaluation of the therapeutic efficacy of vastarel 20 mg (trimetazidine) in cochleovestibular syndromes. A double-blind study versus placebo Ann Otolaryngol Chir Cervicofac 1984; 101: 565-9.
98. Bouccara D. Contribution of vastarel 20 mg (trimetazidine) in the treatment of vertigo: synopsis of clinical trials Ann Otolaryngol Chir Cervicofac. 1999; 116: 43-6.
99. Chaine G, Hullo A, Sahel J, Soubrane G, Espinasse-Berrod MA, Schutz D, et al. Case-control study of the risk factors for age related macular degeneration. France-DMLA Study Group. Br J Ophthalmol 1998; 82: 996-1002.
100. McCord JM. Free radicals and myocordial ischaemia: overview and outlook. Free Rad Biol Med 1988; 4: 9-14.
101. de Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome. Eur Heart J. 1993; 14 Suppl G: 34-40.
102. Maupoil V, Rochette L, Tabard A, Clauser P, Harpey C. Evolution of free radical formation during low-flow ischaemia and reperfusion in isolated rat heart. Cardiovasc Drugs Ther 1990; 4: 791-5.
103. Maridonneau-Parini I. Effect of trimetazidine on membrane changes induced by oxygen free radicals in human red cells. Presse Med 1986; 15: 1762-4.
104. Fabiani JN, Farah B, Vuilleminot A, Lecompte T, Emerit I, Chardigny C, et al. Chromosomal aberrations and neutrophil activation induced by reperfusion in the ischaemic human heart. Eur Heart J 1993; 14: 12-7.
105. Libersa C, Honoré E, Adamantidis M, Rouet E, Dupuis B. Antiischaemic effect of trimetazidine: enzymatic and electric response in a model of in vitro myocardial ischaemia. Cardiovasc Drugs Ther 1990; 4: 808-9.
106. Drake-Holland AJ, Belcher PP, Hynd J, Noble MI. Infarct size in rabbits: a modified method illustrated by the effects of propranolol and trimetazidine. Basic Res Cardiol 1993; 88: 250-8.
107. Hugtenburg JG, Jap TJW, Mathy MJ, Van Heiningen PNM, Bohenenn VA, Heijnis JB, et al. Cardioprotective effect of trimetazidine and nifedipine in guinea-pig hearts subjected to ischaemia. Arch Int Pharmacodyn Ther 1989; 300: 186-208.
108. Lavanchy N, Martin J, Rossi A. Anti-ischaemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 1286: 97-110.
109. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949-58.
110. Fantini E, Athias P, Demaison L, Grynberg A. Protective effects of trimetazidine on hypoxic cardiac myocytes from the rat. Fundam Clin Pharmacol 1997; 11: 427-39.
111. Renaud JF. Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988; 1: 677-86.
112. Lagadic-Gossman D, Le Prigent K, Feuvray D. Effects of trimetazidine on pHi regulation in the rat isolated ventricular myocyte. Brit J Pharmacol 1996; 117: 831-8.
113. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischaemic hypertrophied rat myocardium. Pharmacology 1993; 46: 324-31.
114. Veitch K, Maisin L, Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischaemia and reperfusion. Am J Cardiol 1995; 76: 25B-30B.
115. Salducci MD, Chauves-Monges AM, Tillement JP, Albengres E, Testa B, Carrupt P, et al. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rate liver mitochondria. J Pharmacol Exp Ther 1996; 277: 417-22.
116. Grynberg A, Demaison L. Fatty acid oxydation in the heart. J Cardiovasc Pharmacol 1996; 28: S11-7.
117. Demaison L, Fantini, E, Sentex E, Grynberg A, Athias P. Trimetazidine in vitro influence on heart mitochondrial function. Am J Cardiol 1995; 76: 31B-37B.
118. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism fatty acid oxidation to glucose by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
119. Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001; 12(suppl 1): s8-s11.
120. Mody FV, Singh BN, Mohiuddin IH, Coyle KB, Buxton DB. Hansen HW, et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischaemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998; 82: 42K-49K.
121. Pichon G, Rousseau D, Héliès C, Grynberg A. Contrôle par la Trimetazidine de la balance des substrats énergé tiques du myocyte ventriculaire. Arch Mal Cœur Vaisseaux 1999; 92: 496.
122. Sentex E, Sergiel JP, Lucien A, Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocytes. Mol Cell Biochem 1997; 175: 153-62.
123. Tabbi-Anneni I, Lucien, A, Grynberg A. Trimetazidine effect on phospholipid synthesis en ventricular myocytes: consequences in alpha-adrenergic signaling. Fundam Clin Pharmacol 2003; 17: 51-9
124. Sentex E, Helies C, Rousseau D, Lucien A, Ferrary E, Grynberg A. Influence of Trimetazidine on the synthesis of complex lipids in target organs. Fund Clin Pharmacol 2001; 15: 255-64.
125. Sentex E, Sergiel JP, Lucien A, Grynberg A. Is the Cytoprotective Effect of Trimetazidine Associated with lipid Metabolism? Am J Cardiol 1998; 82: 18K-24K.
126. Zelinski TA, Savard JD, Man RYK, Choy PC. Phosphatidylcholine biosynthesis in isolated hamster heart. J Biol Chem 1980; 225: 11423-8.
127. Vance DE. Glycerolipid biosynthesis in eukaryotes. in « Biochemistry of lipids, lipoproteins and membranes » Vance DE et Vance JE, Eds, Elsevier, Amsterdam 1996; 153-80.
128. Morin D, Elimadi A, Sapena R, Crevat A, Carrupt PA, Testa B, et al. Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol 1998; 123: 1385-94.
129. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles. FEBS Lett 2000; 466: 323-6.
130. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene 2002; 286: 135-41.
131. Lesnefsky EJ, Slabe TJ, Stoll MS, Minkler PE, Hoppel CL. Myocardial ischaemia selectively depletes cardiolipin in rabbit heart subsarcolemmal mitochondria. Am J Physiol 2001; 280: H2770-8.
132. Petrosillo G, Ruggiero FM, Di Venosa N, Paradies G. Decreased complex III activity in mitochondria isolated from rat heart subjected to ischaemia and reperfusion: role of reactive oxygen species and cardiolipin. FASEB J 2003; 17: 714-6.
133. Tabbi-Anneni I, Helies-Toussaint C, Morin D, Bescond-Jacquet A, Lucien A, Grynberg A. Prevention of heart failure in rats by trimetazidine treatment: a consequence or accelerated phospholipid turnover? J Pharmacol Exp Ther 2003; 304: 1003-9.
134. Inci I, Dutly A, Inci D, Boehler A, Weder W. Recipient treatment with trimetazidine improves graft function and protects energy status after lung transplantation. J Heart Lung Transplant 2001; 20: 1115-22.
135. Hauet T, Baumert H, Amor IB, Gibelin H, Tallineau C, Eugene M, et al. Pharmacological limitation of damage to renal medulla after cold storage and transplantation by trimetazidine. J Pharmacol Exp Ther 2000; 292: 254-60.
136. Hauet T, Goujon JM, Vandewalle A, Baumert H, Lacoste L, Tillement JP, et al. Trimetazidine reduces renal dysfunction by limiting the cold ischaemia/reperfusion injury in autotransplanted pig kidneys. J Am Soc Nephrol. 2000; 11: 138-48.
137. Gil-Loyzaga P, Hernandez E, Carricondo F, Simon F, Poch-Broto J. Trimetazidine prevents cochlear lesions induced by intraperitoneal and perilymphatic administration of kainic acid. Brain Res 1999; 826: 95-103.
138. Ozden S, Kildaci B, Muftuoglu S, Cakar N, Yildirim C. Effect of trimetazidine on retinal ischaemia/reperfusion injury in rats. Ophthalmologica 2001; 215: 309-17.
139. Mohand-Said S, Jacquet A, Lucien A, Espinasse-Berrod MA, Frasson Correa De Silva M, Sahel J. Protective effect of trimetazidine in a model of ischaemia-reperfusion in the rat retina. Ophthalmic Res 2002; 34: 300-5.
140. Anderson JR, Khou S, Nawarskas JJ. Ranolazine: a potential new treatment for chronic stable angina. Heart Dis 2001; 3: 263-9.
141. Schofield RS, Hill JA. The use of ranolazine in cardiovascular disease. Expert Opin Investig Drugs 2002; 11: 117-23
142. Aaker A, McCormack JG, Hirai T, Musch TI. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J Cardiovasc Pharmacol 1996; 28: 353-62.
143. McCormack JG, Baracos VE, Barr R, Lopaschuk GD. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. J Appl Physiol 1996; 81: 905-10.
144. Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 1996; 28: 341-50.
145. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation, in normoxic, ischaemic, and reperfused ischaemic rat hearts. Circulation 1996; 93: 135-42.
146. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol 2001; 418: 105-10.
147. Maruyama K, Hara A, Hashizume H, Ushikubi F, Abiko Y. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol 2000; 52: 709-15.
148. Matsumura H, Hara A, Hashizume H, Maruyama K, Abiko Y. Protective effects of ranolazine, a novel anti-ischaemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Jpn J Pharmacol 1998; 77: 31-9.
149. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994 Aug; 28(8): 1231-7.
150. Allely MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol. 1990 Jan; 99(1): 5-6.
151. Black SC, Gralinski MR, McCormack JG, Driscoll EM, Lucchesi BR. J Effect of ranolazine on infarct size in a canine model of regional myocardial ischaemia/reperfusion. Cardiovasc Pharmacol 1994; 24: 921-8.
152. Sabbah HN, Chandler MP, Mishima T, Suzuki C, Chaudry P, Nass O, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002; 8: 416-22.
153. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 2002 23; 91: 278-80.
154. Pinson A, Padieu P. Erucic acid oxidation by beating heart cells in culture. Febs Lett 1974; 39: 88-90.
155. Allely MC, Brown CM, Kenny BA, Kilpatrick AT, Martin A, Spedding M. Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. J Cardiovasc Pharmacol 1993; 21: 869-73.
156. Letienne R, Vie B, Puech A, Vieu S, Le Grand B, John GW. Naunyn Schmiedebergs Arch Pharmacol. 2001; 363: 464-71. Evidence that ranolazine behaves as a weak beta1- and beta2- adrenoceptor antagonist in the rat cardiovascular system.
157. Anderson JR, Khou S, Nawarskas JJ. Ranolazine: a potential new treatment for chronic stable angina. Heart Dis 2001; 3: 263-9.
158. Thadani U, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischaemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 1994; 90: 726-34.
159. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992; 20: 131-8.
160. Wolff AA for the MARISA Investigators. MARISA: Monotherapy assessment of ranolazine in stable angina. J Am Coll Cardiol 2000; 35(Suppl A): 408A.
161. Chaitman BR. for the CARISA Investigators. Improved exercise capacity using a novel pFOX inhibitor as antianginal therapy: results of the Combination Assessment of Ranolazine In Stable Angina (CARISA). Circulation 2001; 104: 2B.
162. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999; 84: 46-50.
163. Charnock JS, Abeywardena M, Tan D, McLennan P. Omega-3 and omega-6 PUFA's have different effects on the phospholipid fatty acid composition of rat myocardial muscle when added to a saturated fatty acid dietary supplement. Nutr Res 1991; 11: 1013-24.
164. Horrobin DF. Omega-6 and omega-3 essential fatty acids in atherosclerosis, Semin Thromb Hemost 1993; 19: 129-37.
165. Nordoy A. Dietary fatty acids and coronary heart disease. Lipids 1999; 34 Suppl: S19-22.
166. Dimmitt SB. Recent insights into dietary fats and cardiovascular disease. Clin Exp Pharmacol Physiol 1995; 22: 204-8.
167. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975; 28: 958-66.
168. Dyerberg J, Jorgensen KA. Marine oils and thrombogenesis. Prog Lipid Res 1982; 21: 255-69.
169. Bjerregaard P, Dyerberg J. Fish oil and ischaemic heart disease in Greenland [letter]. Lancet 1988; 2: 514.
170. Abeywardena MY, McLennan PL, Charnock JS. Differences between in vivo and in vitro production of eicosanoids following long-term dietary fish oil supplementation in the rat. Prostaglandins Leukot Essent Fatty Acids 1991; 42: 159-65.
171. Abeywardena MY, McLennan PL, Charnock JS. Differential effects of dietary fish oil on myocardial prostaglandin 12 and thomboxane A2 production. Am J Physiol 1991; 260: H379-85.
172. Hirai A, Terano T, Tamura Y, Yoshida S. Eicosapentaenoic acid and adult diseases in Japan: epidemiological and clinical aspects. J Intern Med Suppl 1989; 225: 69-75.
173. Knapp HR. Cardiovascular III: Circulation - Blood Pressure Hypotensive effects of w3 fatty acids: mechanistic aspects. In " Health Effects of w3 Polyunsaturated Fatty Acids in Seafoods" 1991; 313-28.
174. Waeber B, Nussberger J, Brunner H. Antihypertenseurs. In « Pharmacologie - Des concepts fondamentaux aux applications thérapeutiques » 1992; 130-53.
175. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988; 318: 549-57.
176. Sellmayer A, Hrboticky N, Weber PC. Lipids in vascular function. Lipids 1999; 34 Suppl: S13-8.
177. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997; 66: 649-59.
178. Horrocks LA, Yeo YK. Docosahexaenoic acid-enriched foods: production and effects on blood lipids. Lipids 1994; 34 Suppl: S313.
179. Charnock JS, Abeywardena MY, McLennan PL. Comparative changes in the fatty acid composition or rat cardiac phospholipids after long term feeding of sunflower seed oil- or tuna fish oil-supplemented diets. Ann Nutr Metab 1986; 30: 393-406.
180. McMurchie EJ. Dietary lipids and the regulation of membrane fluidity and function, in "Advances in membrane fluidity, vol3, Physiological regulation of membrane fluidity" (Aloia RC, Curtain CC and Gordon LH Eds). Alan R Liss Inc. New York, 1988; 189-237.
181. Hock CE, Holahan MA, Reibel DK. Effect of dietary fish oil on myocardial phospholipids and myocardial ischaemic damage. Am J Physiol 1987; 252: H554-60.
182. Voss A, Reinhart M, Sankarappa S, Sprecher H. The metabolism of 7, 10, 13, 16. 19-docosapentaenoic acid to 4, 7, 10, 13, 16, 19-docosahexaenoic in rat liver is dependant on an Δ-4 desaturase. J Biol Chem 1991; 266: 19995-20000.
183. Grynberg A, Fournier A, Sergiel JP, Athias P. Effect of docosahexaenoic acid and eicosapentaenoic acid in the phospholipids of rat heart muscle cells on adrenoceptor responsiveness and mechanism. J Mol Cell Cardiol 1995; 27: 2507-20.
184. Grynberg A, Fournier A, Sergiel JP, Athias P. Membrane DHA versus EPA and the healing function of the Cardiomyocytes through the adrenergic receptors. Lipids 1996. 31: S205-10.
185. Ponsard B, Durot I, Delerive P, Oudot F, Cordelet C, Grynberg A, et al. Cross influence of membrane PUFA and hypoxia neoxygenation on alpha- and beta-adrenergic function of rat cardiomyocytes. Lipids 1999; 34: 457-66.
186. Delerive P, Oudot F, Ponsard B, Talpin S, Sergiel JP, Cordelet C, et al. Hypoxia-Reoxygenation and Polyunsaturated Fatty Acids Modulate Adrenergic Functions in Cultured Cardiomyocytes. J Mol Cell Cardiol 1999; 31: 377-86.
187. Rousseau D, Moreau D, Raederstorff D, Sergiel JP, Rupp H, Muggli R, et al. Is a dietary n-3 fatty acid supplemental able to influence the cardiac effect of the psychological stress. Mol Cell Biochem 1998; 178: 353-66.
188. Rousseau D, Helies-Toussaint C, Moreau D, Raederstorff D, Grynberg A. Dietary n-3 PUFAs affect the blood pressure rise and cardiac impairments in a hyperinsulinemia rat model in vivo. Am J Physiol 2003; 285: H1294-302.
189. McLennan PL, Abeywardena MY, Charnock JS. Dietary fish oil prevents ventricular fibrillalion following coronary artery occlusion and reperfusion. Am Heart J 1988; 116: 709-17.
190. McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Comparative efficacy of n-3 and n-6 polyunsaturated fatty acids in modulating ventricular fibrillation threshold in the marmoset monkey. Am J Clin Nutr 1993; 58: 666-9.
191. McLennan PL, Howe PR, Abeywardena MY, Muggli R, Raederstorff D, Mono M, et al. The cardiovascular protective role of docosahexaenoic acid. Eur J Pharmacol 1996; 300: 83-9.
192. GISSI group. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico [see comments]. Lancet 1999; 354: 447-55.
193. Demaison L, Sergiel JP, Moreau D, Grynberg A. Influence of the Phospholipid n-6/n-3 Polyunsaturated Fatty Acid Ratio on Mitochondrial Oxidative Metabolism Before and After Myocardial Ischaemia. Biochim Biophys Acta 1994; 1227: 53-9.
194. Ovide-Bordeaux S, Grynberg A. Dietary docosahexaenoic acid affects the alteration induced in rat cardiac mitochondrial function in insulin deficiency and insulin resistance. Am J Physiol 2003; Nov 6 [Epub ahead of print].
195. Pepe S, McLennan PL. Modulation of myocardial oxygen requirements by dietary lipids in the isolated erythrocyte perfused working rat heart. J Mol Cell Cardiol 1992; 24: S115.
196. Demaison L, Bouveret P, Grynberg A. Polyunsaturated Fatty Acid Composition and Lipid Metabolism in Cultured Cardiomyocytes and Isolated Working Rat Heart. Nutr Res 1993; 13: 1003-15.
197. Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischaemic recovery of contractile functon. Circulation 2002; 105: 2303-8.
198. Madsen L, Rustan AC, Vaagenes H, Berge K, Dyroy E, Berge RK. Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference. Lipids 1999; 34: 951-63.
199. Hansford RG, Tsuchiya N, Pepe S. Mitochondria in heart ischaemia and aging. Biochem Soc Symp 1999; 66: 141-7.
200. Pepe S, Tsuchiya N, Lakatta EG, Hansford RG. PUFA and aging modulate cardiac mitochondrial membrane lipid composition and Ca2+ activation of PDH. Am J Physiol 1999; 276: H149-58.
201. The EMIP-FR group. Effect of 48h intravenous Trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. Eur Heart J 2000; 21: 1537-46.
202. Tognoni G. Editorial: The EMIP project. Eur Heart J 2000; 21: 1498-9.
203. Grynberg A. The EMIP-FR Study: the evolution of scientific background as a non-controlled parameter. Eur Heart J 2001; 22: 975-7.
204. Lopaschuk GD. Trimetazidine in AMI. Eur Heart J 2001; 22: 977-8.
205. Andoh A, Tsujikawa T, Fujiyama Y. Role of dietary fiber and short-chain fatty acids in the colon. Curr Pharm Des. 2003; 9(4): 347-58.
206. Emanuelia C, Madeddu P. Human tissue kallikrein: new bullet for the treatment of ischemia. Curr Pharm Design 2003; 9(7): 589-97.
207. Kingston R, Kelly CJ, Murray P. The therapeutic role of taurine in ischaemia-reperfusion injury. Curr Pharm Design 2004; 10(19): 2401-10.